Skip to Content
Merck
All Photos(1)

Key Documents

More Documents

SML2035

Sigma-Aldrich

Didox

≥98% (HPLC)

Synonym(s):

3,4-Dihydroxybenzohydroxamic acid, 3,4-Dihydroxyphenylhydroxamic acid, BRN 2096682, CCRIS 7909, N,3,4-Trihydroxybenzamide, NSC 324360, NSC-324360, VF 147

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C7H7NO4
CAS Number:
69839-83-4
Molecular Weight:
169.13
MDL number:
MFCD01667810
UNSPSC Code:
12352200
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

color

white to light brown

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

SMILES string

OC1=CC=C(C(NO)=O)C=C1O

InChI

1S/C7H7NO4/c9-5-2-1-4(3-6(5)10)7(11)8-12/h1-3,9-10,12H,(H,8,11)

InChI key

QJMCKEPOKRERLN-UHFFFAOYSA-N

Biochem/physiol Actions

Didox is a ribonucleotide reductase (RNR) inhibitor that inhibits proliferation of and decreased secretion of cytokines IL-6, IFN-g, TNF-a, IL-2, IL-13, IL-10 and IL-4. Didox inhibits proliferation of tamoxifen-resistant breast cancer cells. Didox is an antioxidant that potentiates the cytotoxic profile of doxorubicin.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ahmed M Al-Abd et al.
European journal of pharmacology, 718(1-3), 361-369 (2013-09-12)
The use of adjuvant therapies in cancer treatment is rationalized by potentiating the efficacy and/or protecting from the major side effects of chemotherapeutics. Didox, besides its antioxidant properties, is an inhibitor for DNA synthesis and repair which might recommend its
Khyati N Shah et al.
Molecular cancer research : MCR, 12(3), 394-407 (2013-12-24)
Acquired tamoxifen resistance develops in the majority of hormone-responsive breast cancers and frequently involves overexpression of the PI3K/AKT axis. Here, breast cancer cells with elevated endogenous AKT or overexpression of activated AKT exhibited tamoxifen-stimulated cell proliferation and enhanced cell motility.
Sahar A Khaleel et al.
Scientific reports, 6, 36855-36855 (2016-11-15)
Doxorubicin (DOX) has limited efficacy in colorectal cancer due to multi-drug resistance. Resveratrol (RES) and didox (DID) are polyhydroxyphenols with potential chemosensitizing effects. Herein, we assessed the chemomodulatory effects of RES and DID to DOX in colorectal cancer cells. Equitoxic

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service